<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 15.3: Cardiovascular Risk Stratification and Endothelial Health</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - RED/GOLD theme for Cardiovascular Health */
        .module-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #dc2626;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #991b1b;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #fef2f2;
            border: 2px solid #ef4444;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #991b1b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #444;
            margin: 30px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs & Text */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #fee2e2 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #991b1b;
        }

        .stat-highlight {
            font-weight: 700;
            color: #dc2626;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #fdfcfb 0%, #f7f3f0 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e5e5;
        }

        .case-study-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Data Tables */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f9fafb;
            padding: 15px;
            font-weight: 600;
            color: #991b1b;
            border-bottom: 2px solid #eee;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
            vertical-align: top;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
            gap: 25px;
            text-align: center;
        }

        .stat-number {
            font-size: 36px;
            font-weight: 700;
            display: block;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #d4a84b;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px;
            margin-bottom: 16px;
            border: 1px solid #eee;
        }

        .reveal-btn {
            background: #991b1b;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #fef2f2;
            border-radius: 8px;
            color: #991b1b;
            font-size: 15px;
        }

        /* Key Takeaways & References */
        .takeaways-box {
            background: #f9fafb;
            padding: 30px;
            border-radius: 14px;
            border: 1px solid #e5e5e5;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.8;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 15: Advanced Cardiovascular & Metabolic Integration</p>
            <h1 class="lesson-title">Lesson 15.3: Cardiovascular Risk Stratification and Endothelial Health</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Expert Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Window of Opportunity</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The Endothelial Shield</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Beyond LDL-C: ApoB Analysis</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Vascular Hot Flashes</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Nutritional Arterial Defense</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Stratification</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the "Window of Opportunity" for hormone therapy and cardiovascular protection.</li>
                <li>Explain the mechanism by which estrogen modulates Nitric Oxide and endothelial function.</li>
                <li>Differentiate between standard lipid panels and advanced markers like ApoB and Lp(a).</li>
                <li>Interpret vasomotor symptoms (VMS) as clinical biomarkers for subclinical atherosclerosis.</li>
                <li>Apply the THRIVE "Inflammation Control" pillar to mitigate arterial stiffness.</li>
            </ul>
        </div>

        <h2 id="section1">1. The 'Window of Opportunity' Hypothesis</h2>
        <p>For decades, the medical community was divided on the cardiovascular effects of Hormone Replacement Therapy (HRT). We now understand that the <span class="highlight">timing of initiation</span> is the most critical variable. This is known as the "Window of Opportunity" or the "Timing Hypothesis."</p>
        
        <p>The core of this hypothesis suggests that estrogen is cardioprotective when the vascular endothelium is healthy (typically in early menopause), but can be potentially harmful if introduced after significant atherosclerotic plaque has already formed. A 2020 secondary analysis of the ELITE trial demonstrated that women starting HRT within <span class="stat-highlight">6 years of menopause</span> showed significantly slower progression of subclinical atherosclerosis (measured by carotid intima-media thickness) compared to those starting 10+ years after the transition.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">30-50%</span>
                    <span class="stat-label">Reduction in CHD Risk (Early Start)</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">10 Years</span>
                    <span class="stat-label">The Critical 'Window' Threshold</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">2.5x</span>
                    <span class="stat-label">Increase in CVD Risk Post-Menopause</span>
                </div>
            </div>
        </div>

        <h2 id="section2">2. The Endothelial Shield: Estrogen and Nitric Oxide</h2>
        <p>The endothelium is not merely a lining of the blood vessels; it is a dynamic endocrine organ. Estrogen acts as a primary "shield" for this system by binding to <span class="highlight">Estrogen Receptor Alpha (ERÎ±)</span> within the vessel walls. This binding stimulates the enzyme <span class="highlight">Endothelial Nitric Oxide Synthase (eNOS)</span>.</p>

        <p>Nitric Oxide (NO) is the body's natural vasodilator. It performs three critical functions:
        <ul class="content-list">
            <li><strong>Vasodilation:</strong> Relaxing smooth muscle cells to maintain healthy blood pressure.</li>
            <li><strong>Anti-thrombotic:</strong> Preventing platelets from sticking to vessel walls.</li>
            <li><strong>Anti-inflammatory:</strong> Inhibiting leukocyte adhesion, a key step in plaque formation.</li>
        </ul>
        </p>

        <p>When estrogen levels plummet, eNOS activity drops, leading to <span class="highlight">endothelial dysfunction</span>. This is the physiological "rusting" of the arteries that precedes hypertension and atherosclerosis. As a Menopause Support Coach, recognizing that a client's rising blood pressure in midlife is often a symptom of this hormonal withdrawalâ€”rather than just "age"â€”is vital for proper stratification.</p>

        <h2 id="section3">3. Why LDL-C is Insufficient: The ApoB Revolution</h2>
        <p>In the <strong>R: Reset Metabolism</strong> pillar of the THRIVE methodology, we move beyond surface-level metrics. Conventional medicine focuses on LDL-C (the weight of cholesterol inside particles). However, cardiovascular risk is driven more by the <span class="highlight">number of atherogenic particles</span> than the total mass of cholesterol.</p>

        <p><strong>Apolipoprotein B (ApoB)</strong> is a superior marker because every single atherogenic particle (VLDL, IDL, and LDL) carries exactly one molecule of ApoB. Therefore, ApoB provides a direct count of the "bullets" that can penetrate the arterial wall.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Standard Interpretation</th>
                        <th>Advanced (ApoB-Centric) Interpretation</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>LDL-C</strong></td>
                        <td>Focuses on the mass of cholesterol.</td>
                        <td>Can be misleadingly low if particles are small and dense.</td>
                    </tr>
                    <tr>
                        <td><strong>ApoB</strong></td>
                        <td>Rarely tested in standard checkups.</td>
                        <td>The gold standard for particle count; target &lt;80 mg/dL for low risk.</td>
                    </tr>
                    <tr>
                        <td><strong>Lipid Particle Size</strong></td>
                        <td>Not considered.</td>
                        <td>Small, dense LDL (Pattern B) is 3x more atherogenic than large, fluffy LDL.</td>
                    </tr>
                    <tr>
                        <td><strong>Lp(a)</strong></td>
                        <td>Ignored.</td>
                        <td>A genetically determined "sticky" LDL particle; high levels indicate high risk regardless of lifestyle.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study 15.3A: The "Lean" Metabolic Risk</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">D</div>
                    <div class="patient-info">
                        <h4>Deborah, 54</h4>
                        <p>Post-menopausal (2 years) | BMI: 23 | Active Lifestyle</p>
                    </div>
                </div>
                <p><strong>Presenting Symptoms:</strong> Deborah's standard lipid panel showed an LDL-C of 130 mg/dL (borderline). Her doctor was "unconcerned" due to her fitness level. However, she reported increasing brain fog and "vascular" hot flashes.</p>
                <p><strong>Advanced Intervention:</strong> We requested an ApoB and NMR LipoProfile. Results showed an ApoB of 115 mg/dL (High) and a high count of small, dense LDL particles.</p>
                <p><strong>Outcome:</strong> Despite her healthy weight, Deborah's lack of estrogen was accelerating endothelial dysfunction. By integrating high-dose Omega-3s (3g/day) and working with her doctor to initiate transdermal estradiol, her ApoB dropped to 85 mg/dL within 4 months, and her arterial stiffness (measured by Pulse Wave Velocity) improved by 12%.</p>
            </div>
        </div>

        <h2 id="section4">4. 'Vascular Hot Flashes' as an Early Biomarker</h2>
        <p>We traditionally view vasomotor symptoms (VMS) as a quality-of-life issue (covered in <strong>Module 1: Track Symptoms</strong>). However, emerging data from the SWAN study (Study of Women's Health Across the Nation) suggests that VMS are actually a window into cardiovascular health.</p>

        <p>A 2023 study published in <i>JAMA Network Open</i> involving 3,000+ women found that those with frequent or persistent hot flashes had a <span class="stat-highlight">50-70% increased risk</span> of cardiovascular disease events over a 20-year follow-up. This is because VMS are not just "heat"; they are a manifestation of autonomic nervous system instability and endothelial dysfunction. Frequent hot flashes are associated with:</p>
        <ul class="content-list">
            <li>Increased carotid artery intima-media thickness (a proxy for plaque).</li>
            <li>Higher levels of pro-inflammatory cytokines (IL-6 and CRP).</li>
            <li>Reduced flow-mediated dilation (FMD), the gold standard for measuring endothelial health.</li>
        </ul>

        <h2 id="section5">5. Inflammation Control for Arterial Stiffness</h2>
        <p>In the <strong>I: Inflammation Control</strong> pillar, we focus on dietary patterns that specifically target <span class="highlight">arterial stiffness</span>. Arterial stiffness is a hallmark of the menopausal transition, often occurring even in the absence of weight gain.</p>

        <h3>The Polyphenol-Nitric Oxide Axis</h3>
        <p>Certain nutrients act as "eNOS mimetics," helping to stimulate nitric oxide production even when estrogen is low. High-polyphenol foodsâ€”specifically those rich in <span class="highlight">anthocyanins</span> and <span class="highlight">flavanols</span>â€”have been shown in meta-analyses to reduce systolic blood pressure by an average of 4-6 mmHg in post-menopausal women.</p>

        <ul class="content-list">
            <li><strong>Cocoa Flavanols:</strong> Improve flow-mediated dilation significantly within 2 hours of ingestion.</li>
            <li><strong>Beetroot Nitrate:</strong> Provides an exogenous source of nitric oxide, bypassing the need for eNOS.</li>
            <li><strong>Pomegranate:</strong> Contains punicalagins that protect LDL from oxidation (the process that makes LDL dangerous).</li>
            <li><strong>Magnesium:</strong> Essential for smooth muscle relaxation; deficiency is a primary driver of menopausal hypertension.</li>
        </ul>

        <h2 id="section6">6. Clinical Stratification: The Practitioner's Checklist</h2>
        <p>As an expert Menopause Support Coach, you must be able to help clients interpret their risk beyond the "normal" ranges on a lab report. Use the following stratification checklist when reviewing a client's cardiovascular health:</p>

        <div class="principle-card">
            <div class="principle-title">1. The "Age-Menopause" Gap</div>
            <p class="principle-text">Is the client within 10 years of their final menstrual period? If yes, the "Window of Opportunity" for HRT-related cardioprotection is open. If no, focus shifts heavily toward aggressive non-hormonal lipid and inflammation management.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">2. VMS Intensity Tracking</div>
            <p class="principle-text">Does the client have "severe" VMS (>7 episodes per day)? This indicates a higher risk profile for subclinical atherosclerosis, regardless of cholesterol levels.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">3. Advanced Lipid Assessment</div>
            <p class="principle-text">Always advocate for ApoB and Lp(a) testing. A client with "normal" LDL but high ApoB is at high risk and requires intervention (The THRIVE <i>Reset Metabolism</i> protocol).</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your mastery of cardiovascular stratification.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is starting HRT 15 years after menopause considered potentially risky for the heart?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">According to the "Window of Opportunity" hypothesis, starting HRT late may be detrimental because estrogen can destabilize existing atherosclerotic plaque that has formed during the 15-year estrogen-deficient gap, potentially leading to a rupture or clot.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Which marker provides a more accurate count of atherogenic particles: LDL-C or ApoB?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">ApoB. Since every atherogenic particle carries exactly one ApoB molecule, it provides a direct count of the total number of particles, whereas LDL-C only measures the mass of cholesterol inside them.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>The <span class="highlight">Window of Opportunity</span> suggests that cardiovascular benefits of HRT are maximized when started within 6-10 years of menopause.</li>
                <li>Estrogen is a vital regulator of <span class="highlight">Nitric Oxide</span>; its loss leads to endothelial dysfunction and arterial stiffness.</li>
                <li><span class="highlight">ApoB</span> is the superior metric for lipid-related risk, especially in metabolically challenged menopausal women.</li>
                <li><span class="highlight">Vasomotor symptoms</span> are not just "flashes"â€”they are clinical indicators of underlying vascular strain.</li>
                <li>Targeted nutrition (polyphenols, nitrates, magnesium) can help maintain vessel elasticity in the absence of estrogen.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Hodis, H. N., et al. (2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol." <i>New England Journal of Medicine.</i></li>
                <li>Thurston, R. C., et al. (2023). "Menopausal Vasomotor Symptoms and Incident Cardiovascular Disease Events." <i>JAMA Network Open.</i></li>
                <li>Sniderman, A. D., et al. (2021). "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review of Recent Evidence." <i>JAMA Cardiology.</i></li>
                <li>Maki, P. M., et al. (2020). "The 2020 Menopause Management Guidelines." <i>The North American Menopause Society (NAMS).</i></li>
                <li>Crandall, C. J., et al. (2020). "Vasomotor Symptoms and Coronary Artery Calcium Progression in the SWAN Study." <i>Menopause Journal.</i></li>
                <li>Rosano, G. M., et al. (2021). "The Endothelium as a Target for Estrogen Action in Postmenopausal Women." <i>Climacteric.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Menopause Support Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Confidential Professional Content.</p>
        </footer>
    </div>
</body>

</html>